Skip to Main Content

Paper Details

Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover).
Clin Cancer Res
10
2021
BRCA, BRCA reversion, Carboplatin, HER2, PATIENTS, Paclitaxel, Platinum, Veliparib, carboplatin, ctDNA, fatigue, gBRCA, germline breast cancer susceptibility gene (gBRCA)-associated breast cancer, nausea, paclitaxel, patients, plasma circulating tumor DNA, platinum, veliparib, vomiting
Author NameAffiliation
Vered StearnsThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Teresa HelstenUniversity of California San Diego Moores Cancer Center
David MaagAbbVie Inc.
  • 1 - 3

Datasets

Release 1.2